Pittsburgh, PA (PRWEB) April 15, 2015
Qrono is pleased to participate in the Buzz of BIO Contest for the 2015 BIO International Convention. Hosted by the Biotechnology Industry Organization (BIO), this year's convention will take place June 15-18 at the Pennsylvania Convention Center in Philadelphia, Pennsylvania. During the Buzz of BIO contest, industry leaders will vote for companies they would like to see present at the conference. The community voting period ends at 5:00 PM ET on April 21, 2015 at: http://convention.bio.org/buzzofbio/
“We are very excited to be nominated for the Buzz of BIO in the Pipelines of Promise category,” stated Larry Zana, CEO of Qrono. “Our computational drug delivery technology provides unprecedented ability to rapidly reformulate approved drugs and NCEs as long-acting products with improved therapeutic and economic benefits. It has already generated a pipeline of ten long-acting, complex generics, including three generic versions of currently approved products. Due to the speed of our formulation modeling process, we expect our pipeline to double within the next year. We are grateful in advance to everyone for their consideration and vote.”
Qrono’s computational drug delivery technology collapses the time and cost needed to create long-acting, controlled release formulations, while at the same time reducing clinical trial and regulatory risk by means of in vivo predictions. Extensions to this technology in the form of long-acting in vitro-in vivo correlations (IVIVCs) could revolutionize the regulatory approval process for long-acting and locally-acting medications.
About Qrono Inc.
Qrono Inc. is a specialty pharmaceutical company enabling the development of better medications, stronger patient adherence, improved patient outcomes, and faster time-to-market using a proprietary technology to create long-acting formulations that release their active ingredient over days, weeks, or months with a single administration. Qrono reformulates approved drugs and creates new, long-acting medications with improved clinical and economic benefits. Qrono’s product pipeline of complex generics focuses on therapeutic areas where long-acting medicines offer high therapeutic and economic value, such as addressing high non-adherence or solving specific drug delivery challenges. Qrono’s computational drug delivery technology can design long-acting medicines much faster than the legacy practice, while at the same time reducing regulatory and technical risk.
About the BIO International Convention
The annual BIO International Convention is the largest global event for the biotechnology industry. The Convention attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on the major trends affecting the industry.